Evidence map›Paper›PMID 30470842›Full record

ArticleCancer gene therapy2019

Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.

Qing-Ming Wang, Guang-Yu Lian, Yuan Song, Zhi-Da Peng, Sheng-Hua Xu, Yi Gong

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Overcoming biological barriers to improve solid tumor immunotherapy.Drug delivery and translational research · 2021
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Qing-Ming WangDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China. ddupcy@sina.com.
Guang-Yu LianDepartment of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Yuan SongDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Zhi-Da PengDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Sheng-Hua XuDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Yi GongDepartment of Obstetrics and Gynaecology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China. gongyi0112@sina.com.
Nanchang University · CNChinese University of Hong Kong · CNFirst Affiliated Hospital of Nanchang University · CNSecond Affiliated Hospital of Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the molecular mechanisms for the development of non-Hodgkin lymphoma (NHL) will improve our ability to cure the patients. qRT-PCR was applied for the examination of the efficiency of shRNA for DNMT1, the expression of suppressor genes, miRNA-152. The MTT analysis, cell cycle analysis, clonal formation, and apoptotic analysis were used to examine the functions of DNMT1 and miR-152 in lymphoma cells. Methylation-specific polymerase chain reaction (MSP) was used to examine the methylation of tumor suppressor genes. The dual luciferase assay and western blot were used to validate if DNMT1 is the target of miR-152. For the in vivo experiments, the lymphoma cells were injected into the nude mice for quantification of the tumor growth after transfection of miR-152 mimics. Knockdown of DNMT1 by shRNA (sh-DNMT1) in OCI-Ly10 and Granta-159 cells significantly upregulated the expression of tumor suppressor genes (SOCS3, BCL2L10, p16, p14, and SHP-1) via decreasing their methylation level. At the cellular level, we found sh-DNMT1 inhibited the proliferation, clonal formation and cell cycle progression and induced the cell apoptosis of lymphoma cells. Furthermore, we found miR-152 can downregulates the expression of DNMT1 via directly targeting the gene. Overexpression of miR-152 also increased the expression of tumor suppressor genes SOCS3 and SHP-1. And miR-152 also can inhibit the cell proliferation and induce the cell apoptosis. Moreover, we found overexpression of miR-152 significantly repressed the tumor growth with decreased DNMT1 expression and increased expression of tumor suppressor genes in vivo. Our study demonstrates that miR-152 can inhibit lymphoma growth via suppressing DNMT1-mediated silencing of SOCS3 and SHP-1. These data demonstrate a new mechanism for the development of NHL and this may provide a new therapeutic target for NHL.

Indexed as

AnimalsApoptosisCell Line, TumorCell ProliferationDNA (Cytosine-5-)-Methyltransferase 1Down-RegulationGene Knockdown TechniquesGenes, Tumor SuppressorHEK293 CellsHeterograftsHumansLymphoma, Non-HodgkinMiceMicroRNAsProtein Tyrosine Phosphatase, Non-Receptor Type 6Signal TransductionDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanMicroRNAsMIRN152 microRNA, humanProtein Tyrosine Phosphatase, Non-Receptor Type 6PTPN6 protein, humanSOCS3 protein, humanSuppressor of Cytokine Signaling 3 Protein

Identifiers

PMID30470842
OpenAlexW2901102887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.